Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of Intravenous (IV) Administration of a Human Monoclonal Antibody Against Tick-borne Encephalitis Virus in Healthy Adults.

NCT07377253 is registered in ClinicalTrials.gov with Giuseppe Pantaleo as lead sponsor.

NCT NCT07377253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07377253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of Intravenous (IV) Administration of a Human Monoclonal Antibody Against Tick-borne Encephalitis Virus in Healthy Adults.
Lead sponsor
Giuseppe Pantaleo
Phase
Phase 1
Overall status
Not yet recruiting
Start date
January 1, 2026
Completion date
October 31, 2026
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

the tick-borne encephalitis virus (tbev)